- Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters
- Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps in premarket CNBC
- Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms Fast Company
- Novo Nordisk Falls Most on Record After New Weight Drug Disappoints Bloomberg
- Novo Nordisk A/S (NVO) Fell as its Weight Loss Drug Faced Supply Constraints Yahoo Finance